NCT05122091View on ClinicalTrials.gov

Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

November 5, 2021

Primary Completion Date

November 5, 2024

Study Completion Date

November 30, 2024

Conditions
Gastric CancerGastroEsophageal CancerFruquintinibSOX
Interventions
DRUG

Fruquintinib + SOX

Fruquintinib：5mg qd for 2 weeks on and 1 week off, q3w； SOX: Tegafur gimeracil oteracil potassium capsule: 40-60mg bid（dosage according to body surface area），d1-14，q3w； Oxaliplatin：130mg/m2，intravenous (IV) ，d1，q3w.

Trial Locations (1)

Unknown

RECRUITING

Guangxi Medical University Cancer Hospital, Nanning

All Listed Sponsors
lead

Guangxi Medical University

OTHER